Pulmatrix Quarterly Balance Sheets Chart
Quarterly
|
Annual
Pulmatrix Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
|---|---|---|---|---|
| assets | ||||
| current assets: | ||||
| cash and cash equivalents | 16,300,000 | 19,173,000 | 21,336,000 | 25,791,000 |
| accounts receivable | 570,000 | 928,000 | 841,000 | 418,000 |
| prepaid expenses and other current assets | 712,000 | 742,000 | 899,000 | 1,019,000 |
| total current assets | 17,582,000 | 20,843,000 | 23,229,000 | 27,381,000 |
| property and equipment | 1,108,000 | 1,158,000 | 1,166,000 | 279,000 |
| operating lease right-of-use asset | 10,094,000 | 10,309,000 | 10,686,000 | 277,000 |
| long-term restricted cash | 1,472,000 | 1,472,000 | 1,472,000 | 1,472,000 |
| other long-term assets | 135,000 | 176,000 | 217,000 | 1,984,000 |
| total assets | 30,391,000 | 33,958,000 | 36,770,000 | 31,393,000 |
| liabilities and stockholders’ equity | ||||
| current liabilities: | ||||
| accounts payable | 721,000 | 1,915,000 | 707,000 | 929,000 |
| accrued expenses and other current liabilities | 1,677,000 | 947,000 | 2,535,000 | 1,201,000 |
| operating lease liability | 383,000 | 429,000 | 199,000 | 358,000 |
| deferred revenue | 363,000 | 618,000 | 988,000 | 1,109,000 |
| total current liabilities | 3,144,000 | 3,909,000 | 4,429,000 | 3,597,000 |
| deferred revenue, net of current portion | 3,727,000 | 4,038,000 | 4,347,000 | |
| operating lease liability, net of current portion | 8,229,000 | 8,327,000 | 8,422,000 | |
| total liabilities | 11,373,000 | 15,963,000 | 16,889,000 | 7,944,000 |
| commitments and contingencies | ||||
| stockholders’ equity: | ||||
| preferred stock, 0.0001 par value — 500,000 shares authorized; 6,746 shares designated series a convertible preferred stock; no shares issued and outstanding at march 31, 2024 and december 31, 2023 | ||||
| common stock | ||||
| additional paid-in capital | 305,790,000 | 305,592,000 | 305,395,000 | 305,189,000 |
| accumulated deficit | -286,772,000 | -287,597,000 | -285,514,000 | -281,740,000 |
| total stockholders’ equity | 19,018,000 | 17,995,000 | 19,881,000 | 23,449,000 |
| total liabilities and stockholders’ equity | 30,391,000 | 33,958,000 | 36,770,000 | 31,393,000 |
| restricted cash | 153,000 | 153,000 | ||
| preferred stock, 0.0001 par value — 500,000 shares authorized; 6,746 shares designated series a convertible preferred stock; no shares issued and outstanding at december 31, 2023 and 2022 | ||||
| preferred stock, 0.0001 par value — 500,000 shares authorized; 6,746 shares designated series a convertible preferred stock; no shares issued and outstanding at september 30, 2023 and december 31, 2022 | ||||
| preferred stock, 0.0001 par value — 500,000 shares authorized; 6,746 shares designated series a convertible preferred stock; no shares issued and outstanding at june 30, 2023 and december 31, 2022 |
We provide you with 20 years of balance sheets for Pulmatrix stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Pulmatrix. Explore the full financial landscape of Pulmatrix stock with our expertly curated balance sheets.
The information provided in this report about Pulmatrix stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.